NCT05306132View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202

PHASE1UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

ASKC202

Dosage Forms: Tablets; Administration: Oral administration

Trial Locations (3)

Unknown

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Xiangya Hospital Central South University, Changsha

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

INDUSTRY